Brainstorm Cell Therapeutics (NASDAQ:BCLI) Issues Earnings Results, Misses Estimates By $0.02 EPS

Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.02), Zacks reports.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ BCLI opened at $1.19 on Monday. The business’s 50-day simple moving average is $1.71 and its 200-day simple moving average is $2.00. Brainstorm Cell Therapeutics has a 52 week low of $1.05 and a 52 week high of $11.25. The firm has a market cap of $6.79 million, a price-to-earnings ratio of -0.25 and a beta of 0.74.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics in a report on Wednesday, March 26th. They set a “hold” rating on the stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.